OBJECTIVE: To compare the effectiveness and risk profile of newer methods for endoscopic ablation of the prostate against the current standard of transurethral resection. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic and paper records in subject area up to March 2006. REVIEW METHODS: We searched for randomised controlled trials of endoscopic ablative interventions that included transurethral resection of prostate as one of the treatment arms. Two reviewers independently extracted data and assessed quality. Meta-analyses of prespecified outcomes were done using fixed and random effects models and reported using relative risk or weighted mean difference. RESULTS: We identified 45 randomised controlled trials meeting the inclusion criteria and reporting on 3970 participants. The reports were of moderate to poor quality, with small sample sizes. None of the newer technologies resulted in significantly greater improvement in symptoms than transurethral resection at 12 months, although a trend suggested a better outcome with holmium laser enucleation (random effects weighted mean difference -0.82, 95% confidence interval 1.76 to 0.12) and worse outcome with laser vaporisation (1.49, -0.40 to 3.39). Improvements in secondary measures, such as peak urine flow rate, were consistent with change in symptoms. Blood transfusion rates were higher for transurethral resection than for the newer methods (4.8% v 0.7%) and men undergoing laser vaporisation or diathermy vaporisation were more likely to experience urinary retention (6.7% v 2.3% and 3.6% v 1.1%). Hospital stay was up to one day shorter for the newer technologies. CONCLUSIONS: Although men undergoing more modern methods of removing benign prostatic enlargement have similar outcomes to standard transurethral resection of prostate along with fewer requirements for blood transfusion and shorter hospital stay, the quality of current evidence is poor. The lack of any clearly more effective procedure suggests that transurethral resection should remain the standard approach.
OBJECTIVE: To compare the effectiveness and risk profile of newer methods for endoscopic ablation of the prostate against the current standard of transurethral resection. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic and paper records in subject area up to March 2006. REVIEW METHODS: We searched for randomised controlled trials of endoscopic ablative interventions that included transurethral resection of prostate as one of the treatment arms. Two reviewers independently extracted data and assessed quality. Meta-analyses of prespecified outcomes were done using fixed and random effects models and reported using relative risk or weighted mean difference. RESULTS: We identified 45 randomised controlled trials meeting the inclusion criteria and reporting on 3970 participants. The reports were of moderate to poor quality, with small sample sizes. None of the newer technologies resulted in significantly greater improvement in symptoms than transurethral resection at 12 months, although a trend suggested a better outcome with holmium laser enucleation (random effects weighted mean difference -0.82, 95% confidence interval 1.76 to 0.12) and worse outcome with laser vaporisation (1.49, -0.40 to 3.39). Improvements in secondary measures, such as peak urine flow rate, were consistent with change in symptoms. Blood transfusion rates were higher for transurethral resection than for the newer methods (4.8% v 0.7%) and men undergoing laser vaporisation or diathermy vaporisation were more likely to experience urinary retention (6.7% v 2.3% and 3.6% v 1.1%). Hospital stay was up to one day shorter for the newer technologies. CONCLUSIONS: Although men undergoing more modern methods of removing benign prostatic enlargement have similar outcomes to standard transurethral resection of prostate along with fewer requirements for blood transfusion and shorter hospital stay, the quality of current evidence is poor. The lack of any clearly more effective procedure suggests that transurethral resection should remain the standard approach.
Authors: A P Verhagen; H C de Vet; R A de Bie; A G Kessels; M Boers; L M Bouter; P G Knipschild Journal: J Clin Epidemiol Date: 1998-12 Impact factor: 6.437
Authors: Natasha Wiebe; Ben Vandermeer; Robert W Platt; Terry P Klassen; David Moher; Nicholas J Barrowman Journal: J Clin Epidemiol Date: 2006-04 Impact factor: 6.437
Authors: Samer Fathi Al-Rawashdah; Antonio Luigi Pastore; Yazan Al Salhi; Andrea Fuschi; Vincenzo Petrozza; Angela Maurizi; Ester Illiano; Elisabetta Costantini; Giovanni Palleschi; Antonio Carbone Journal: World J Urol Date: 2017-02-27 Impact factor: 4.226
Authors: Annika Herlemann; Kerstin Wegner; Alexander Roosen; Alexander Buchner; Philipp Weinhold; Alexander Bachmann; Christian G Stief; Christian Gratzke; Giuseppe Magistro Journal: World J Urol Date: 2017-05-17 Impact factor: 4.226
Authors: Jeffery C Wheat; Timothy L Hall; Christopher R Hempel; Charles A Cain; Zhen Xu; William W Roberts Journal: Urology Date: 2009-11-22 Impact factor: 2.649